Most of silymarin’s anti-inflammatory hepatoprotective effects have focused on cytokine release; however, Zhang et al. (2018) observed that silybin significantly impedes NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in NAFLD by elevating NAD+ levels, which as a result preserves the effect of the NAD+-dependent α-tubulin deacetylase sirtuin (SIRT)2 and restrains the activation of the acetylated α-tubulin promoted NLRP3 inflammasome, thus indicating the potential of silybin for targeting the NAD+/SIRT2 pathway [54]. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.